SAN ANTONIO, July 09, 2025--bioAffinity Technologies' CyPath® Lung detects Stage 1A lung cancer when imaging was inconclusive ...

Sky Sports News reporter Keith Downie delivers the latest on Newcastles transfer plans, potential departures and how sporting director Paul Mitchells imminent exit will affect the window in a Q&A ...

SAN ANTONIO - bioAffinity Technologies, Inc. (NASDAQ:BIAF; BIAFW), a company specializing in noninvasive early-stage cancer diagnostics with a market capitalization of $4.11 million, has announced the ...

Dr. Downie has authored more than 30 peer-reviewed publications, many centered on innovation in bronchoscopy, early lung cancer diagnosis and medical device development.

Downie, who has over 30 years of experience in pulmonary medicine and clinical research, will bring his expertise in lung cancer diagnosis and medical device development to the company.

Dr. Downie’s career has been marked by significant contributions to pulmonary medicine, including authoring over 30 peer-reviewed publications and leading FDA-approved research programs.

SAN ANTONIO, May 20, 2025--Pulmonologist Gordon Downie, MD, PhD, joins bioAffinity Technologies as Chief Medical Officer.